Kiora Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Kiora Pharmaceuticals's revenue and earnings are forecast to decline at 15.5% and 37.4% per annum respectively while EPS is expected to decline by 36.5% per annum.

Anahtar bilgiler

-37.4%

Kazanç büyüme oranı

-36.5%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.7%
Gelir büyüme oranı	-15.5%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	22 Aug 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem

May 21

Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Oct 13

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:KPRX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	1	-15	N/A	N/A	2
12/31/2025	2	-11	N/A	N/A	3
12/31/2024	17	6	N/A	N/A	3
6/30/2024	16	3	5	5	N/A
3/31/2024	16	2	7	7	N/A
12/31/2023	N/A	-13	-10	-10	N/A
9/30/2023	N/A	-13	-9	-9	N/A
6/30/2023	N/A	-12	-10	-10	N/A
3/31/2023	N/A	-12	-11	-11	N/A
12/31/2022	N/A	-14	-10	-10	N/A
9/30/2022	N/A	-17	-11	-11	N/A
6/30/2022	N/A	-15	-11	-11	N/A
3/31/2022	N/A	-15	-11	-11	N/A
12/31/2021	N/A	-14	-11	-11	N/A
9/30/2021	0	-9	-10	-9	N/A
6/30/2021	0	-8	-9	-9	N/A
3/31/2021	0	-7	-8	-7	N/A
12/31/2020	0	-7	-7	-7	N/A
9/30/2020	N/A	-8	-8	-8	N/A
6/30/2020	N/A	-10	-8	-8	N/A
3/31/2020	N/A	-10	-8	-8	N/A
12/31/2019	3	-7	-8	-8	N/A
9/30/2019	3	-7	-8	-8	N/A
6/30/2019	3	-7	-9	-8	N/A
3/31/2019	3	-8	-9	-9	N/A
12/31/2018	2	-11	-11	-11	N/A
9/30/2018	2	-11	-11	-10	N/A
6/30/2018	1	-12	-10	-10	N/A
3/31/2018	1	-13	N/A	-11	N/A
12/31/2017	0	-13	N/A	-6	N/A
9/30/2017	1	-14	N/A	-7	N/A
6/30/2017	1	-13	N/A	-7	N/A
3/31/2017	1	-14	N/A	-7	N/A
12/31/2016	1	-13	N/A	-8	N/A
9/30/2016	1	-12	N/A	-8	N/A
6/30/2016	0	-10	N/A	-6	N/A
3/31/2016	N/A	-8	N/A	-4	N/A
12/31/2015	N/A	-17	N/A	-4	N/A
9/30/2015	N/A	-14	N/A	-3	N/A
6/30/2015	N/A	-13	N/A	-3	N/A
3/31/2015	N/A	-12	N/A	-2	N/A
12/31/2014	N/A	-2	N/A	-1	N/A
9/30/2014	N/A	-2	N/A	-1	N/A
6/30/2014	N/A	-3	N/A	-2	N/A
3/31/2014	N/A	-4	N/A	-3	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: KPRX's earnings are forecast to decline over the next 3 years (-37.4% per year).

Kazançlar ve Piyasa: KPRX's earnings are forecast to decline over the next 3 years (-37.4% per year).

Yüksek Büyüme Kazançları: KPRX's earnings are forecast to decline over the next 3 years.

Gelir ve Pazar: KPRX's revenue is expected to decline over the next 3 years (-15.5% per year).

Yüksek Büyüme Geliri: KPRX's revenue is forecast to decline over the next 3 years (-15.5% per year).

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if KPRX's Return on Equity is forecast to be high in 3 years time

Kiora Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates increase by 64%, revenue downgraded

Price target decreased by 69% to US$3.83

Price target increased by 42% to US$17.50

Price target decreased by 56% to US$20.00

Price target increased by 39% to US$65.50

No longer forecast to breakeven

Recent updates

Investor sentiment improves as stock rises 16%

New major risk - Market cap size

Consensus EPS estimates increase by 64%, revenue downgraded

New major risk - Market cap size

Investor sentiment deteriorates as stock falls 16%

Kiora Pharmaceuticals, Inc. Announces Board and Committee Changes

Investor sentiment improves as stock rises 21%

Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem

Kiora Pharmaceuticals, Inc., Annual General Meeting, May 01, 2024

New major risk - Revenue and earnings growth

Price target decreased by 69% to US$3.83

New major risk - Share price stability

Price target increased by 42% to US$17.50

Kiora Pharmaceuticals, Inc. Announces Board Changes

New major risk - Revenue and earnings growth

Price target decreased by 56% to US$20.00

Kiora Pharmaceuticals, Inc. Appoints Carmine Stengone as an Independent Director

Kiora Pharmaceuticals Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Price target increased by 39% to US$65.50

Kiora Pharmaceuticals, Inc. and The Royal Adelaide Hospital Announce Dosing Has Commenced in the Phase 1 First-In-Human Trial for KIO-301

Kiora Pharmaceuticals, Inc. Receives Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases

High number of new directors

Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Kiora Pharma announces 1-for-40 reverse stock split

Kiora Pharmaceuticals, Inc. Appoints Melissa Tosca as Executive Vice President of Finance

Kiora Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

High number of new directors

Kiora Pharmaceuticals, Inc., Annual General Meeting, Sep 23, 2022

Kiora Pharmaceuticals reports 1H results

Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing

Kiora Pharmaceuticals prices $5.2M underwritten public offering

Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201

Kiora Pharmaceuticals, Inc. Announces Brian M. Strem Will Assume Role of its Principal Financial and Accounting Officer

Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Kiora Pharmaceuticals, Inc. announced delayed 10-Q filing

Kiora Pharmaceuticals, Inc. Appoints Susan L. Drexler as Interim Chief Financial Officer

Kiora Pharmaceuticals, Inc. announced delayed annual 10-K filing

Kiora Pharmaceuticals, Inc. Appoints Michael Meluzio as Principal Financial Officer and Principal Accounting Officer

Kiora Pharmaceuticals, Inc. Announces Resignation of Sarah Romano as Chief Financial Officer, Effective February 25, 2022

Kiora Pharmaceuticals, Inc. Announces Executive Changes

No longer forecast to breakeven

EyeGate Pharmaceuticals, Inc. Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation

Price target decreased to US$11.83

EyeGate Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $10.750013 million.

Director Steven Boyd has left the company

Director I. Maher has left the company

EyeGate Pharmaceuticals, Inc. Announces First Patient Dosed for PP-001 in A Phase 2 Proof-Of-Concept Ocular Surface Inflammation Study

No longer forecast to breakeven

Price target decreased to US$13.08

Full year 2020 earnings released: US$1.77 loss per share (vs US$2.23 loss in FY 2019)

New 90-day high: US$7.30

EyeGate Pharmaceuticals, Inc. Announces Board Appointments

New 90-day high: US$6.63

EyeGate Pharmaceuticals announces $8M private placement

Price target raised to US$12.83

EyeGate Pharmaceuticals, Inc. (NasdaqCM:EYEG) entered into a share purchase agreement to acquire Panoptes Pharma GES.M.B.H for $15 million.

New 90-day high: US$5.21

EyeGate surge in premarket as it acquires Panoptes Pharma for $4M

Earnings beat expectations

New 90-day low: US$3.57

Price target lowered to US$11.17

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin